Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Source :: GlobeNewswire. June 4, 2024
Publication Year :: 2024
Abstract: SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1 Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN FRANSCISO, Calif., June 04, 2024 [...]

Subjects :: Boehringer Ingelheim GmbH -- Forecasts and trends -- Product development -- Planning
Business plans -- Forecasts and trends
Hepatitis -- Forecasts and trends
Clinical trials -- Forecasts and trends
Business planning -- Forecasts and trends
Pharmaceutical industry -- Product development -- Forecasts and trends -- Planning
Company business planning
Market trend/market analysis
Banking, finance and accounting industries
Business

Tools